ATEA PHARMACEUTICALS, INC.— Sankey Diagram
Quarterly mode · period ending 2021-12-31 · SEC EDGAR
ComparingFY2021 (Q4) vs FY2020 (Q4)
Revenue
$192M
Gross Profit
$192M
Operating Income
$121M
Net Income
$117M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2021 (Q4) |
|---|---|
| Revenue | $192M |
| COGS | $0 |
| Gross Profit | $192M |
| R&D | $58M |
| SG&A | $0 |
| D&A | $7K |
| Other OpEx | $13M |
| Operating Income | $121M |
| Interest Exp. | $0 |
| Other Non-Op | $0 |
| Pretax Income | $121M |
| Tax | $4M |
| Net Income | $117M |
QuarterCharts · SEC EDGAR data · AVIR · Comparing FY2021 (Q4) vs FY2020 (Q4)